The management of pulmonary tuberculosis (TB) in Scotland in 1993 was studied by asking the physicians responsible for all 321 adult cases of the disease notified that year to complete a standardized questionnaire relating to drug treatment and bacteriology. The response rate to the questionnaire was 100%. Isoniazid and rifampicin were used together in initial therapy in 98.4% of cases, while pyrazinamide was prescribed in 90.3% of cases, broadly in keeping with existing treatment guidelines. However, considerable variability was observed both in the drug regimens employed, and in the duration of initial and continuation phases of chemotherapy. Treatment regimens were therefore frequently at variance with published recommendations.
Introduction
In 1990 the British Thoracic Society (BTS) published recommendations for the treatment of pulmonary tuberculosis (TB) (1). These were based on evidence generated from important clinical trials (2-6), and proposed that isoniazid (H), rifampicin (R) and pyrazinamide (Z) be used together in the initial 2 months, to be followed by isoniazid and rifampicin together for a further 4 months continuation therapy (1).
The extent to which these recommendations have been implemented in Scotland has not been formally assessed. The Scottish Respiratory Tuberculosis (SRTB) Survey published comprehensive data relating to the clinical management of pulmonary TB between 1977 and 1985 (7). Among several interesting findings, the Survey noted that ethambuto1 (E) was far more commonly used as part of initial therapy in the early 1980s than was pyrazinamide though the latter was gaining in popularity (7). We aimed to determine how widely the BTS guidelines have been adopted in Scotland by examining data pertaining to treatment of pulmonary TB in adults in Scotland in 1993. We also sought to examine whether changes in treatment or microbiological information had emerged when compared to historical data from the 1980s (7).
Methods
The Consultant in Public Health Medicine for each of Scotland's Health Board areas (to whom notifications of TB are made) kindly supplied us with details of all notified cases of TB in 1993. The named specialist physician responsible for each case was sent a standardized questionnaire designed to determine details of the initial and continuation therapy used, and to establish microbiological details. Questions asked in the questionnaire are presented in the Appendix.
In all cases microbiological information was derived from reports issued by the local microbiology laboratory, together with identification and sensitivity testing of Mycobacterium tuberculosis cultures by the Scottish Mycobacteria Reference Laboratory, which also acted as the primary laboratory for the Lothian region.
Several items in the questionnaire were identical to questions posed in previous SRTB Surveys, allowing broad comparisons to be made with data generated up to 1985. The response rate to the questionnaire was 100%. The derivation of the patient groups studied is illustrated in Fig. 1 . In total 369 patients were diagnosed as having TB confined solely to the lungs (as detailed in 8). Eighteen were under 15 years of age and were excluded from analysis. In 30 of the remaining patients no information relating to treatment was available; in 12 of these the diagnosis of pulmonary TB was made after death, one left the country, and no treatment details were provided for the remaining 17. In keeping with data presented by other groups (7,9) these patients were excluded from analysis, leaving a population of 321 adult patients with a diagnosis of pulmonary TB for whom detailed information was available. Information pertaining to initial chemotherapy was available for all 321 patients. However, no data were generated relating to continuation therapy in 55 cases -32 died before continuation treatment was considered, insufficient information was available to determine details of continuation treatment in 20 and three were lost to followup. Information on continuation treatment was therefore available for 266 patients (Fig. 1) .
Patient details were coded numerically to ensure confidentiality, and stored in a computerized registry.
Results

PATIENTS
The median age of the patients was 62 years (range 15-92 years). Two hundred and eighty-seven patients (89.4%) were Caucasian. The ethnic origin of the remaining patients was as follows, Indian sub-continent in 27 (8.4%), African continent in 6 (1.9%), and Chinese sub-continent in one.
THERAPY Initial therapy
The frequency of use of individual drugs in initial therapy is shown in (984%). The use of at least three drugs in initial treatment was recorded in 307 patients (956%). The duration of initial treatment was extremely variable. This is exemplified by the duration of initial treatment prescribed for patients receiving isoniazid, rifampicin and pyrazinamide as initial therapy, followed by isoniazid and rifampicin as continuation therapy (the HRZ/HR regimen) shown in Fig. 2 . Of the 171 patients receiving HRZlHR for whom information was available, 103 (60.2%) received the recommended 8 or 9 weeks of initial treatment. However, 11 patients (6.4%) received less than 8 weeks of HRZ, and 57 (33.3%) were prescribed more than 9 weeks of HRZ, of whom 18 (10.4%) were not switched to HR continuation treatment until after 12 weeks. A similar pattern was observed for the other treatment regimens employed (data not shown).
Continuation therapy
The frequency with which individual drugs were used in continuation therapy is shown in Table 2 . The combination Fig. 3 . A high proportion of patients in each group was treated for longer than the recommended 6-month period (as illustrated in Fig. 4 , using the example of patients completing treatment with the recommended HRZ/HR regimen), while a minority received treatment for less than 6 months.
The attending physician considered that chemotherapy was completed as planned in 135 (78.5%) of the patients prescribed the recommended HRZ/HR regimen. Of the remaining 37 patients 13 were still receiving some form of chemotherapy 1 year after diagnosis, 13 died during treat- ment, five were lost to follow-up, two were non-compliant with treatment, and incomplete information was available on the final four. Satisfactory completion of treatment was achieved in a lower proportion of patients when other treatment regimens were employed: 67.7% for those receiving HRZE/HR, 75.0% for those receiving HRE/HR, 42.9% for the group receiving ethambutol in continuation, and 45.8% for the group receiving other regimens. In total 193 patients (60.1%) among the total population of 321 were considered to have completed treatment as planned.
Sixty-two patients died within 1 year of the diagnosis of pulmonary TB. The mean age of this group of patients was 71.3 years. The majority of deaths were considered to be unrelated to TB. TB was considered to be a primary cause of death in 17 of these patients, for whom the mean age was 71.5 years. Detailed information was available for 10 of these 17 patients. Six had received anti-tuberculous chemotherapy for between 5 and 11 days before death and two had received prolonged, non-standard regimens. Among patients in whom chemotherapy was completed 18 (9.3%) were said to have required a modification of treatment because of drug toxicity.
MICROBIOLOGY
In 36 cases (11.2%) no microbiological samples were received, and in 11 cases (3.4%) no data regarding microbiology were available, leaving detailed information for 274 cases. Mycobacteriurn tuberculosis was identified on both sputum smear and culture in 139 cases (50.8%), on culture alone in 66 cases (24.1%), and by sputum smear alone in 25 cases (9.1%). In total bacteriological confirmation by smear and/or culture was obtained for 230 patients (83.9%) from whom samples were sent. In the remaining 44 cases (16.1%) samples were sent but no bacteriological confirmation was obtained. 
Discussion
These data indicate that since the publication of BTS recommendations for the management of pulmonary TB (1) there has been a considerable rise in the use of pyrazinamide as part of initial therapy in Scotland (from approximately 35% of cases in 1985 to around 90% in 1993) with a reduction in the administration of ethambutol (92% in 1985 compared with 20% in 1993). These findings are in keeping with the increased use of pyrazinamide in England and Wales (9,lO). However, the prescription of pyrazinamide was already increasing steadily prior to the publication of the BTS recommendations (7,9). The combination of isoniazid and rifampicin remained the backbone of both initial and continuation treatment. The continued use of ethambutol in 20% of initial therapy may reflect a preference on the part of some physicians to cover the possibility of drug resistance or atypical mycobacteria while awaiting culture and sensitivity results. BTS recommendations suggest incorporating ethambutol where isoniazid resistance is suspected (1). Our data suggests an approximate rate of isoniazid resistance of 6% while almost 20% of patients received ethambutol in initial therapy. Reasons for the high prevalence of ethambutol prescription in continuation therapy remain unclear. Several comparisons can be made between elements of our data and information generated in Scotland in 1985 by the SRTB survey (7) and in England and Wales in 1988 and 1993 (9,lO). It should be noted however that there were small differences in the composition of cases included in these studies. The SRTB survey, unlike this study, included only patients admitted to hospital as part of pulmonary TB management, and among this number included 5% of patients under the age of 15. The BTS study in England and Wales differed from this study in that 36% of patients were non-Caucasian and that patients with no known bacteriological results were excluded from final analysis. However, allowing for these small differences broad comparisons can be made.
A high proportion of patients received chemotherapy for longer than 6 months in Scotland in 1993. This was largely attributable to prolongation of the initial phase of treatment. A similar pattern emerged in England and Wales in 1988 (9). A continued tendency to prescribe 9 months of chemotherapy partly explained the prolonged mean duration of treatment in England and Wales, but this accounted for few cases in Scotland.
Our findings indicate that treatment was completed as intended by the attending physician in only 60% of cases. This compares with a corresponding figure of 59.3% in 1985 (7). Approximately 58% of patients completed therapy as planned in England and Wales in 1988 (9).
The proportion of patients with pulmonary TB who died within 1 year of treatment was higher in 1993 (16.8%) than in 1985 (13.5%). However, a higher proportion of those who died in the 1993 survey were over the age of 65 (data not shown) and it seems likely that the increased death rate simply reflects the more elderly age distribution.
The proportion of deaths in which TB was considered a primary cause was higher than in England and Wales (9). Interestingly, in the few cases in which detailed information was available there was a distinct trend for deaths attributable to TB to occur early in the course of treatment. This might imply that technologies allowing earlier diagnosis and treatment (11) may reduce mortality attributable to TB. An alternative inference might be that extra vigilance is required in elderly patients newly diagnosed, and treated, for pulmonary TB.
The incidence of recorded drug toxicity necessitating modification of therapy was lower (go/o) than that in England and Wales (14%) (9). A possible explanation for this observation is under-reporting of drug reactions by patients andlor physicians. The current study did not allow for an assessment of whether toxicity contributed to mortality.
The percentage of patients in whom bacteriological confirmation was obtained via sputum smear and/or culture was almost identical to that observed in Scotland in 1985, and slightly higher than in 1983 and 1984 (7). Despite the high rate of microbiological confirmation, the diagnosis of TB was apparently made in the absence of any clinical samples being submitted in over 10% of patients. This compares with a rate of approximately 5% in the 1980s. Furthermore, a high proportion of cases proved to be culture positive but sputum-smear negative, or sputumsmear positive and culture negative, while in 44 cases samples were sent but no bacteriological confirmation was possible. The absence of concomitantly positive smear and culture results may reflect laboratory techniques, insufficient or technically inadequate clinical sampling, or the coincidental use of treatments that might clear M. tubeuculosis in clinical samples (e.g. ciprofloxacin or aminoglycosides). In cases where no bacteriological confirmation could be obtained an alternative possibility could have been diagnostic inaccuracy. Where possible clinical samples of high quality should be sent for bacteriological confirmation, not least to prevent emergence of multi-drug resistance in Scotland (12) .
Taken together, these data illustrate that the rate of satisfactory completion of treatment, and the rate of microbiological confirmation were no different from rates recorded in Scotland 8 years previously. There has been some movement toward adoption of the drug regimens recommended in published guidelines, but major obstacles still lie in the way of their widespread application. Principal among these are trends for prolonged duration of treatment regimens, continued use of non-standard regimens, and frequent cases in which no clinical samples are sent to the laboratory.
Closer adherence to existing guidelines, and increased pursuit of microbiological confirmation appear not only to be practicable, but also highly desirable given that less satisfactory completion of therapy and lack of laboratory data were associated with non-standard drug regimens in this study. 
